$2.24
0.29.80%
At Close: -
$2.07
-0.17-7.59%
After Hours: 7:59 PM EDT
15 minutes delayed
Comments
Loading...
CytoMed Therapeutics
GDTCNASDAQ
want to know what
the Bulls & Bears Say?
CytoMed Therapeutics (NASDAQ:GDTC) Stock, Analyst Ratings, Price Targets, Forecasts
CytoMed Therapeutics Ltd has a consensus price target of $5 based on the ratings of 1 analysts. The high is $5 issued by Benchmark on June 11, 2024. The low is $5 issued by Benchmark on June 11, 2024. The 3 most-recent analyst ratings were released by Benchmark on June 11, 2024, December 4, 2023, and July 21, 2023, respectively. With an average price target of $5 between Benchmark, there's an implied 141.55% upside for CytoMed Therapeutics Ltd from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Benchmark
1calculated from analyst ratings
Analyst Ratings for CytoMed Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 06/11/2024 | Buy Now | 141.55% | Benchmark | Bruce Jackson | $5 → $5 | Reiterates | Speculative Buy → Speculative Buy | Get Alert |
| 12/04/2023 | Buy Now | 141.55% | Benchmark | Bruce Jackson | → $5 | Reiterates | Speculative Buy → Speculative Buy | Get Alert |
| 07/21/2023 | Buy Now | 141.55% | Benchmark | Bruce Jackson | → $5 | Initiates | → Speculative Buy | Get Alert |
FAQ
What is the target price for CytoMed Therapeutics (GDTC) stock?
The latest price target for CytoMed Therapeutics (NASDAQ:GDTC) was reported by Benchmark on June 11, 2024. The analyst firm set a price target for $5.00 expecting GDTC to rise to within 12 months (a possible 141.55% upside). 3 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for CytoMed Therapeutics (GDTC)?
The latest analyst rating for CytoMed Therapeutics (NASDAQ:GDTC) was provided by Benchmark, and CytoMed Therapeutics reiterated their speculative buy rating.
When was the last upgrade for CytoMed Therapeutics (GDTC)?
There is no last upgrade for CytoMed Therapeutics
When was the last downgrade for CytoMed Therapeutics (GDTC)?
There is no last downgrade for CytoMed Therapeutics.
When is the next analyst rating going to be posted or updated for CytoMed Therapeutics (GDTC)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CytoMed Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CytoMed Therapeutics was filed on June 11, 2024 so you should expect the next rating to be made available sometime around June 11, 2025.
Is the Analyst Rating CytoMed Therapeutics (GDTC) correct?
While ratings are subjective and will change, the latest CytoMed Therapeutics (GDTC) rating was a reiterated with a price target of $5.00 to $5.00. The current price CytoMed Therapeutics (GDTC) is trading at is $2.07, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.